Page 58 - Memora anual Fundación CIEN 2017
P. 58
therapeutic and neuroimaging data. This systematic tion (treatment of spasticity in patients with multiple
gathering of information, from the moment the pa- sclerosis). The trial will be carried out in nine Spanish
tient enters the study until it is transferred to another healthcare centers (five in Madrid, two in San Se-
Day Center or passes away, allows for the genera- bastián, one in Barcelona and one in Santander).
tion of a large database of clinical data that can be The trial has already been approved by the Ethics
exploited in itself or in relation to the neuroimaging Committee and the Spanish Agency for Medicines
and/or neuropathological data. and Health Products and during this year it has wor-
ked on its organization and logistics and on the hi-
In 2017, there were 55 new admissions in the Day ring of participating centers and suppliers.
Care Center and in the Residence, of which 34 sig-
ned the consent to participate in the multidiscipli- 4. Other ongoing research projects: The Department
nary periodic evaluations. Together with the 43 of Neurology, with its own resources or, more often
baseline evaluations, a total of 455 clinical evalua- than not, in collaboration with other CAFRS or exter-
tions (semi-annual frequency), 44 studies of brain MRI nal groups, is carrying out several other research pro-
(annual frequency) and 344 analytical studies were jects. Most of them are mainly based on information
carry out. o from the Vallecas Project or CAFRS databases. In
other instances, information provided by various co-
3. Clinical-Therapeutical Research: Progress has llaborators is used.
been made in the Sat-CIEN-02 project, an acade-
mic non-profit academic clinical trial funded by the • Detection of proteins in the tear as biomarkers
Alzheimer's Association USA whose Principal Investi- of Alzheimer's Disease
gator is Dr. Isidro Ferrer and CIBERNED acts as pro-
moter. This double-blind clinical trial consists in the • Project REGISTRY. International multi-center
treatment during 26 weeks of a group of 60 patients observational study conducted by the
with cognitive impairment or incipient dementia at- European Huntington's Disease Group (EHDN).
tributable to Alzheimer's-type degeneration, ran- Finished in December 2017.
domly distributed in 4 arms (one placebo and three
doses of active medication). The product that will be • Influence of the regular intake of drugs on
evaluated is a cannabinoid mixture that is already cognitive performance in the Vallecas Project
registered in the Spanish market for another indica- cohort
• Psychotic symptoms and vascular risk factors
in Alzheimer's disease
• Behavioral disorders and neuropathological
findings in Alzheimer's disease
PERIODIC MULTIDISCIPLINARY ASSESSMENTS DURING 2017
Admissions in Day Centre and Residence 55
Informed Consents 34
Baseline Assessments 43
Clinical Evaluations 455
Brain MRI Studies 44
Blood testing 344
CIEN Foundation Annual Report 2017 / 58
